US1488061029 - Common Stock
All three of these high-flying stocks could have more room to run.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
A recent FDA announcement may have just put one company in the lead.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT). Such investors are...
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge.
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT). Such investors are...
Catalent experiences a 1% increase after filing its 10-Q late due to internal control matters, following its acquisition by Novo Holdings.
Catalent experiences a 1% increase after filing its 10-Q late due to internal control matters, following its acquisition by Novo Holdings.
Even more revenue is on the way from additional sales of Wegovy.
Nearly $4B opportunity awaits pick-and-shovel players in the booming weight loss drug market dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). Read more here.
Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.
The Federal Trade Commission will review if drugmakers like Eli Lilly can find alternative suppliers in Novo Nordisk's purchase of Catalent and its plants.
AstraZeneca (AZN) is reportedly looking to reduce its reliance on contract manufacturers like Catalent (CTLT) by ramping up in-house production. Read more here.
Catalent Inc. Q2 earnings report shows -$0.24 Non-GAAP EPS, missing estimates by $0.22.